Targeting IDH1 as a pro-senescent therapy in high-grade serous ovarian cancer
E. S. Dahl, R. Buj, K. E. Leon, J. M. Newell, B. G. Bitler, N. W. Snyder, K. M. Aird
This study identifies IDH1 as a therapeutic target in HGSC by showing its role in promoting metabolic adaptation and epigenetic repression, leading to senescence when inhibited.
bioRxiv · Nov 17, 2018Cancer Biology